Leap Therapeutics (NASDAQ:LPTX) Lowered to Neutral Rating by Robert W. Baird

Robert W. Baird lowered shares of Leap Therapeutics (NASDAQ:LPTXFree Report) from an outperform rating to a neutral rating in a research report released on Wednesday, Marketbeat.com reports. The firm currently has $1.25 price objective on the stock, down from their prior price objective of $9.00.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.50 price objective on shares of Leap Therapeutics in a research note on Thursday, January 16th.

Read Our Latest Stock Analysis on LPTX

Leap Therapeutics Trading Up 7.9 %

Shares of NASDAQ LPTX opened at $0.56 on Wednesday. The company has a market cap of $21.46 million, a price-to-earnings ratio of -0.29 and a beta of 0.17. Leap Therapeutics has a 12 month low of $0.51 and a 12 month high of $4.79. The stock has a 50-day moving average price of $2.74 and a two-hundred day moving average price of $2.73.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after acquiring an additional 50,194 shares during the period. Simplify Asset Management Inc. increased its holdings in Leap Therapeutics by 67.4% in the third quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after purchasing an additional 425,626 shares during the period. HighTower Advisors LLC bought a new position in Leap Therapeutics during the 3rd quarter worth $65,000. HB Wealth Management LLC lifted its holdings in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after buying an additional 26,150 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Leap Therapeutics by 268.2% in the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after buying an additional 58,094 shares during the last quarter. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

(Get Free Report)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

Read More

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.